Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: The lactate dehydrogenase-to-albumin ratio (LAR) has been acknowledged as an independent prognostic factor for multiple diseases. However, its prognostic significance in extensive-stage small cell lung cancer (ES-SCLC) patients treated with immune checkpoint inhibitors (ICIs) remains ambiguous. This study aims to explore the influence of LAR on the prognosis of ES-SCLC patients undergoing ICIs combined with chemotherapy.
Abstract Although previous studies have linked body composition to immunotherapy efficacy, comprehensive multidimensional analyses with biological explanations remain lacking. This study integrated eight independent cohorts comprising 2,132 non-small cell lung cancer (NSCLC) patients, including five immune checkpoint inhibitor prognostic cohorts (n = 1,919), two bulk RNA-seq cohorts (n = 190), and one prospective single-cell RNA-seq cohort (n = 23).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
